Erin Patterson, jailed for the deadly “mushroom lunch” killings, is approved to receive Ozempic through taxpayer-funded arrangements while serving a life sentence in a Melbourne prison. Multiple outlets report the approval covers access to the diabetes medication during imprisonment.
The reports note Ozempic is primarily a prescription drug for type 2 diabetes and that it is also commonly used off-label for weight loss. While the outlets focus on the public funding aspect, they provide consistent information about Patterson’s conviction, her current imprisonment setting, and the fact that the approval is for in-prison access to the medicine.
Across the articles, the main difference is the emphasis on the controversy around taxpayer spending and the framing of the drug’s broader reputation rather than its approved medical use. All accounts describe the approval as ongoing during her incarceration and indicate the decision has been made for prison-administered treatment.
